Latest News on IQV

Financial News Based On Company


Advertisement
Advertisement

Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer

https://www.pfizer.com/news/articles/learning_at_the_rate_of_evidence_how_ai_is_reshaping_r_d_at_pfizer
Pfizer is transforming its R&D operations by integrating AI across the entire drug development process, from discovery to pharmacovigilance. The ambitious goal is to halve the time from idea to first-in-human trials and then halve the time to approval by leveraging petabytes of proprietary data and AI models like FLOWR for molecule design and GENESIS for safety monitoring. This initiative aims to accelerate decision-making, enhance scientific judgment, and ultimately deliver breakthroughs to patients faster, all while maintaining rigorous trust, privacy, and regulatory standards.

Glenmark Launches Authorized Generic Version of Pfizer's INLYTA in US

https://medicaldialogues.in/news/industry/pharma/glenmark-launches-authorized-generic-version-of-pfizers-inlyta-in-us-183345
Glenmark Pharmaceuticals Inc., USA has launched Axitinib Tablets, 1 mg and 5 mg, which is an Authorized Generic version of Pfizer's INLYTA® (axitinib) tablets. This move aims to expand access to quality, affordable medicines for patients in the United States, particularly in the oncology sector. According to IQVIA sales data, U.S. annual sales of INLYTA® Tablets were approximately $538.4 million for the 12-month period ending September 2026.

IQVIA GETS A CLEAN BILL OF HEALTH: Eastern District of California Dismisses Claims Against IQVIA Holding That No Specific Searches Means No Privacy Claim

https://natlawreview.com/article/iqvia-gets-clean-bill-health-eastern-district-california-dismisses-claims-against
The Eastern District of California has dismissed privacy claims against IQVIA, the health data company behind Drugs.com, ruling that plaintiffs failed to specify the actual search terms or medications they looked up. The court emphasized that a hypothetical search cannot substitute for real content in privacy claims. While the dismissal allows for amendment, it sets a higher bar for health privacy lawsuits, requiring plaintiffs to provide concrete details of the information allegedly shared.

IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know

https://www.tradingview.com/news/zacks:3fd9a62c7094b:0-iqvia-stock-jumps-59-in-6-months-here-s-what-you-should-know/
IQVIA (IQV) shares have significantly outperformed the market, climbing 58.8% in the past six months due to strong performance in its Clinical Research & Commercial Solutions segments, driven by rising outsourcing demand and healthcare information services. The company's competitive edge is further enhanced by its adoption of AI, which optimizes clinical trials and operations, alongside robust operational efficiencies contributing to its strong bottom line. Despite this performance, IQV currently holds a Zacks Rank #3 (Hold).

Keith Meister Sells $61M Of Illumina Stock As Shares Slip Below Sale Price

https://www.benzinga.com/trading-ideas/insider-trades/26/11/63249108/keith-meister-sells-61m-of-illumina-stock-as-shares-slip-below-sale-price
Keith Meister of Corvex Management sold 280,091 shares of Illumina Inc (NASDAQ:ILMN) for $61.1 million on November 9, 2026. The sale occurred at a weighted-average price of $218.12 per share, and Illumina's stock subsequently slipped to $208.85, 4.25% below the sale price. Meister significantly reduced his holdings but still beneficially owned 215,713 shares after the transaction.
Advertisement

Thermo Fisher Scientific (TMO) Dividend And Bond Moves Leave Valuation Questions Open

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-dividend-and-bond-moves-leave-v
Thermo Fisher Scientific (TMO) has announced a quarterly cash dividend of $0.47 per share and completed new Swiss franc bond offerings, providing investors with insight into its shareholder returns and funding strategy. While the stock has seen significant gains recently, analyst consensus views it as fairly valued at $750.92, whereas a DCF model suggests it might be overvalued at its current price of $699.44. These mixed signals, combined with an upcoming executive retirement, create valuation questions for investors.

Iqvia Holdings evp Eric Sherbet sells $1.24M in company shares

https://www.investing.com/news/insider-trading-news/iqvia-holdings-evp-eric-sherbet-sells-124m-in-company-shares-93CH-5023856
Eric Sherbet, EVP and General Counsel at IQVIA Holdings Inc., sold company stock totaling over $1.23 million on November 9, 2026, near the stock's 52-week high. These sales followed the exercise of stock appreciation rights. Despite the sales, IQVIA's stock is considered undervalued by InvestingPro analysis, and the company recently surpassed Q3 earnings and revenue expectations, leading to a raised financial outlook.

Form 4 IQVIA Holdings Inc: Eric Sherbet (Officer) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-iqvia-holdings-inc-eric-sherbet-officer-for-9-november-93CH-5701524
This article reports on a Form 4 filing for IQVIA Holdings Inc., detailing an insider transaction by officer Eric Sherbet on November 9. Form 4 filings are mandatory for company insiders to disclose changes in their ownership of the company's stock. The article provides the basic information about the filing and links to further details.

Iqvia Holdings evp Eric Sherbet sells $1.24M in company shares

https://ca.investing.com/news/stock-market-news/iqvia-holdings-evp-eric-sherbet-sells-124m-in-company-shares-93CH-4954995
Eric Sherbet, Executive Vice President and General Counsel at IQVIA Holdings Inc. (NASDAQ:IQV), sold 4,446 common shares for $1,239,678 and an additional 3,990 common shares for $1,112,172 on November 9, 2026. Prior to these sales, Mr. Sherbet acquired 8,436 shares by exercising stock appreciation rights totaling $1,112,033. Despite the sales, InvestingPro analysis suggests IQVIA is undervalued, and the company recently reported strong Q3 earnings, exceeding expectations and raising its financial outlook.

Iqvia Holdings evp Eric Sherbet sells $1.24M in company shares

https://uk.investing.com/news/stock-market-news/iqvia-holdings-evp-eric-sherbet-sells-124m-in-company-shares-93CH-4979410
Eric Sherbet, EVP and General Counsel at IQVIA Holdings Inc., sold company stock totaling over $2.35 million on November 9, 2026, including two transactions of 4,446 shares and 3,990 shares. These sales occurred after he acquired 8,436 shares through stock appreciation rights, and he now directly holds 20,999 shares. The transactions follow a strong 57% surge in the stock over the past six months and coincide with IQVIA reporting better-than-expected Q3 earnings and an increased financial outlook.
Advertisement

IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-6ed20b7b-baf72c56e947
Shares of IQVIA Holdings Inc. (IQV) experienced a 1.25% decline on Thursday, closing at $271.11. This underperformance occurred during a broader negative trading session where the S&P 500 Index fell 0.35% and the Dow Jones Industrial Average dropped 0.36%. This marked the third consecutive day of losses for the stock.

LYR ETF Holdings List — AMEX:LYR

https://www.tradingview.com/symbols/AMEX-LYR/holdings/
This article lists the top holdings of the Lyrical U.S. Value Equity ETF (AMEX:LYR) as of November 10, 2026. The fund's composition details the weight, shares, and market value for each company. Top holdings include IQVIA Holdings Inc, NetApp, Inc., and Corpay, Inc.

Business Wire: The Trade Desk Reports Third Quarter 2026 Financial Results

https://www.thetradedesk.com/press-room/the-trade-desk-reports-third-quarter-2026-financial-results
The Trade Desk announced its third-quarter 2026 financial results, with revenue of $736 million and GAAP diluted earnings per share of $0.08. Despite results being ahead of expectations, the company acknowledged operating below its growth targets, attributing this to market conditions. The Trade Desk highlighted strong customer retention, new AI-driven platform innovations like Kokai Zuma, expanded CTV integrations with Netflix and HBO Max, and an additional $731 million increase to its share repurchase authorization.

Mettler-Toledo International Inc. (MTD) stock price, news, quote and history

https://au.finance.yahoo.com/quote/MTD/
Mettler-Toledo International Inc. (MTD) stock is currently trading at $1,740.92, down 0.46%. The company, which manufactures and supplies precision instruments across various sectors, has a market capitalization of $34.628 billion. Analysts have an average 1-year target estimate of $1,712.50, with JP Morgan recently maintaining a "Neutral" rating and raising its price target to $1840.

Form 144 IQVIA HOLDINGS INC. For: 10 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-iqvia-holdings-inc-for-10-november-93CH-4970388
This article announces the filing of Form 144 for IQVIA Holdings Inc. on November 10. Form 144 indicates an insider's intent to sell restricted or controlled securities. The article provides the title and date of the filing.
Advertisement

Form 144 IQVIA HOLDINGS INC. For: 10 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-iqvia-holdings-inc-for-10-november-93CH-5692632
This article announces the filing of Form 144 for IQVIA Holdings Inc. on November 10. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider trading activity. The document is provided by Investing.com.

Form 144 IQVIA HOLDINGS INC. For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-iqvia-holdings-inc-for-10-november-93CH-4945294
This article from Investing.com announces the filing of Form 144 for IQVIA Holdings Inc. on November 10. Form 144 relates to the proposed sale of restricted securities. The brief notice indicates that further details would be available within the full Form 144 filing.

Form 4 IQVIA Holdings Inc: Morris Leslie Wims (Director) For: 5 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-iqvia-holdings-inc-morris-leslie-wims-director-for-5-november-93CH-5692256
This article reports on a Form 4 filing for IQVIA Holdings Inc. concerning director Morris Leslie Wims, dated November 5. Form 4 filings are regulatory documents used to disclose changes in beneficial ownership of securities by company insiders. The article provides the basic announcement without further details on the transaction.

Form 4 IQVIA Holdings Inc: Jim Fasano (Director) For: 5 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-iqvia-holdings-inc-jim-fasano-director-for-5-november-93CH-5692258
This article reports on a Form 4 filing for IQVIA Holdings Inc., indicating that Jim Fasano, a director, made a transaction on November 5. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The article provides the basic announcement without further details on the nature of the transaction.

Form 4 IQVIA Holdings Inc: John G. Danhakl (Director) For: 5 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-iqvia-holdings-inc-john-g-danhakl-director-for-5-november-93CH-5692252
This article reports on a Form 4 filing for IQVIA Holdings Inc., indicating an insider transaction by Director John G. Danhakl on November 5. The brief piece from Investing.com provides a direct notification of this financial disclosure relevant to the company's stock performance.
Advertisement

LYR ETF Profile: Dividends, Returns (AMEX:LYR)

https://www.tradingview.com/symbols/AMEX-LYR/profile/
The Lyrical U.S. Value Equity ETF (LYR) aims for long-term capital growth, with $1.22 billion in assets under management and an expense ratio of 0.75%. The fund, issued by Lyrical Asset Management GP LLC, primarily invests in U.S. equities with a focus on value, holding significant exposure to sectors like Finance and Electronic Technology. LYR does not pay dividends and trades at a slight discount to its NAV.

Form 4 IQVIA Holdings Inc: John G. Danhakl (Director) For: 5 November

https://ca.investing.com/news/stock-market-news/form-4-iqvia-holdings-inc-john-g-danhakl-director-for-5-november-93CH-4944815
This article reports on a Form 4 filing for IQVIA Holdings Inc., detailing an insider transaction by John G. Danhakl, a Director, on November 5. Form 4 filings are legally required documents submitted to the SEC by company insiders, indicating changes in their ownership of company stock. This specific filing signals a transaction by a key board member of IQVIA.

A 134-share grant brings IQVIA (IQV) director John G. Danhakl's deferred shares to 3,423.

https://www.stocktitan.net/sec-filings/IQV/form-4-iqvia-holdings-inc-insider-trading-activity-19d5502246c6.html
IQVIA Holdings Inc. director John G. Danhakl received a grant of 134 deferred shares on November 5, 2026, increasing his total deferred-share holdings to 3,423. These deferred shares are convertible into common shares upon settlement, which occurs when he ceases to be a director, upon a change in control, or upon his death, with no expiry date. The transaction, filed as a Form 4, indicates a value of $35K for the granted shares at a price of $264.88 per share.

Form 4 IQVIA HOLDINGS INC. For: Nov 05 Filed by: DANHAKL JOHN G

https://www.streetinsider.com/SEC+Filings/Form+4+IQVIA+HOLDINGS+INC.+For%3A+Nov+05+Filed+by%3A+DANHAKL+JOHN+G/27316728.html
This SEC Form 4 filing reports changes in beneficial ownership of IQVIA Holdings Inc. (IQV) stock by John G. Danhakl, a director of the company. On November 5, 2026, Danhakl acquired 134 deferred shares, each convertible into one share of common stock, at a price of $264.88 per share, bringing his total beneficial ownership to 3,423 deferred shares. These deferred shares settle upon his cessation as a director, a change in control, or death.

Form 4 IQVIA HOLDINGS INC. For: Nov 05 Filed by: Fasano Jim

https://www.streetinsider.com/SEC+Filings/Form+4+IQVIA+HOLDINGS+INC.+For%3A+Nov+05+Filed+by%3A+Fasano+Jim/27316730.html
Jim Fasano, a Director at IQVIA Holdings Inc. (IQV), filed a Form 4 detailing deferred share transactions. On November 5, 2026, Fasano acquired 154 deferred shares, convertible into common stock of IQVIA Holdings Inc. These shares become settleable upon cessation as a director, a change in company control, or death.
Advertisement

After acquiring 144 deferred shares, IQVIA (IQV) director Goggins holds 5,441.

https://www.stocktitan.net/sec-filings/IQV/form-4-iqvia-holdings-inc-insider-trading-activity-ed59906dde49.html
IQVIA Holdings Inc. director Colleen A. Goggins acquired 144 deferred shares on November 5, 2026, bringing her total holdings to 5,441 deferred shares. These deferred shares are convertible into common stock on a one-for-one basis upon her ceasing to be a director, a change in control, or her death, and have no expiry date. The transaction was reported in an SEC Form 4 filing.

A 154-share grant brings director Jim Fasano’s deferred holdings in IQVIA (IQV) to 6,422 shares.

https://www.stocktitan.net/sec-filings/IQV/form-4-iqvia-holdings-inc-insider-trading-activity-343a66e066b8.html
IQVIA Holdings Inc. director Jim Fasano received a grant of 154 deferred shares on November 5, 2026, increasing his direct deferred-share holdings to 6,422 shares. These deferred shares are convertible into common stock upon settlement, which occurs when Fasano ceases to be a director, upon a change in control, or upon his death, with no expiry date. The grant is detailed in an SEC Form 4 filing.

A $1.24M sale of 4,446 shares is proposed by IQVIA (IQV) officer Eric Sherbet.

https://www.stocktitan.net/sec-filings/IQV/144-iqvia-holdings-inc-sec-filing-8039a74215fd.html
IQVIA Holdings Inc. officer Eric Sherbet has proposed the sale of 4,446 common shares, valued at approximately $1,239,678.18, with an approximate sale date of November 9, 2026. The shares were acquired through stock appreciation rights from IQVIA Holdings Inc. on the same date, with cash listed as the nature of payment. Morgan Stanley Smith Barney LLC is named as the broker for this transaction.

How $5 Billion Buyback At Thermo Fisher Scientific (TMO) Has Changed Its Investment Story

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/how-5-billion-buyback-at-thermo-fisher-scientific-tmo-has-ch
Thermo Fisher Scientific (TMO) has authorized a new US$5 billion share repurchase program, maintained its dividend at US$0.47 per share, and issued CHF 280 million in Swiss franc bonds. These actions highlight the company's active management of its capital structure and ownership mix, funding its broad life sciences operations. While these capital allocation decisions don't alter the core business drivers, they reinforce Thermo Fisher Scientific's commitment to returning capital to shareholders, alongside strategic operational milestones.

Cortellis: Life Sciences Intelligence Platform

https://casrai.org/guides/cortellis
This guide provides an overview of Clarivate's Cortellis suite, a life sciences intelligence platform integrating biomedical, clinical, regulatory, and commercial data. It details the platform's utility for research sponsors, biotechnology firms, and CROs in assessing pipelines, designing clinical protocols, and navigating global compliance. The article also covers its modular intelligence domains, access methods, strengths, limits, and alternatives.
Advertisement

Earnings Beat Might Change The Case For Investing In Medpace Stock (MEDP)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/earnings-beat-might-change-the-case-for-investing-in-medpace
Medpace Holdings reported better-than-expected Q3 2026 results, with record awards supporting strong earnings and revenue, despite moderated top-line growth. The company is balancing increased demand for clinical development with risks like cancellations and margin variability, which remains a key concern for investors. Analysts project continued earnings growth and revenue increases for Medpace by 2029.

IQVIA Holdings Inc. (IQV) Seasonal returns chart

https://au.finance.yahoo.com/quote/IQV/seasonality/
The article provides a seasonal returns chart for IQVIA Holdings Inc. (IQV), showing average monthly price returns from 2016 to 2026. It includes current stock information, showing IQV's closing price and after-hours trading data. The page also features general market data for Australia, US, Europe, and Asian markets.

IQVIA Holdings Inc. (IQV) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/IQV/seasonality/
The article provides a seasonal returns chart for IQVIA Holdings Inc. (IQV), showing average monthly price returns from 2016 to 2026. It includes current stock information, indicating a slight gain during after-hours trading. The data is presented in the context of Yahoo Finance's market data offerings.

ICON (ICLR) Launches FIRECREST AI Video Engine For Clinical Trial Communications

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iclr/icon/news/icon-iclr-launches-firecrest-ai-video-engine-for-clinical-tr
ICON plc (NasdaqGS:ICLR) has launched its FIRECREST AI-Directed Video Engine, an AI-powered tool designed to automate and standardize clinical trial communications for sites and patients. This new platform aims to enhance productivity and streamline workflows within ICON's existing FIRECREST clinical technology suite, reinforcing the company's focus on leveraging digital tools to improve operational efficiency. The move is expected to contribute to operating leverage and the commercial appeal of ICON's platform, rather than immediate revenue growth, with investors encouraged to monitor its adoption and impact on business wins.

CBRE Group, Inc. (CBRE) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/CBRE/
This article provides a detailed overview of CBRE Group, Inc. (CBRE) stock, including its current price, performance metrics, and key financial data. It also outlines the company's business segments, recent news, analyst ratings, and comparative performance against the S&P 500. The information helps investors understand CBRE's market position and investment potential.
Advertisement

Missed Thermo Fisher Scientific's Run? What Holders Had To Believe

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/missed-thermo-fisher-scientifics-run-what-holders-had-to-bel
Thermo Fisher Scientific's stock has returned 24.8% over the past year despite mixed market signals. The article explores the contrasting bullish and bearish narratives that investors faced, highlighting that the recent run effectively prices in the company's ability to convert pharma, biotech, and bioproduction momentum into durable organic growth, a point that conflicts with some current fair value estimates. It also touches upon a related business that provides essential testing for health data chips and drives robotics in data centers, indicating further growth potential if life sciences computing demand continues.

IQVIA Holdings Inc. (IQV.MX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/IQV.MX/seasonality/
The article provides a seasonal returns chart for IQVIA Holdings Inc. (IQV.MX), showing the average monthly price return between 2020 and 2026. It indicates that the data is based on a delayed quote from Mexico, with the latest closing price at 5,213.94 MXN.

IQVIA Holdings Inc. (IQV.MX) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/IQV.MX/seasonality/
The article provides a seasonal returns chart for IQVIA Holdings Inc. (IQV.MX) on Yahoo Finance. It displays the average monthly price return for the stock from 2020 to 2026. The current stock price and market status are also shown.

Charles River's Q3 Earnings on Deck: What's in Store for the Stock?

https://es.tradingview.com/news/zacks:72fc1c098094b:0-charles-river-s-q3-earnings-on-deck-what-s-in-store-for-the-stock/
Charles River Laboratories International (CRL) is set to release its Q3 2026 earnings, with analysts projecting a 4.8% revenue decline but 22.6% year-over-year EPS growth. The Research Models and Services (RMS) segment is expected to remain under pressure due to lower demand and recent divestitures, while Discovery and Safety Assessment (DSA) may see improved demand in biopharmaceuticals. Manufacturing Solutions is anticipated to benefit from strength in Microbial Solutions and recent technological advancements, despite some divestitures.

IQVIA Holdings Inc. (IQV) stock price, news, quote and history

https://au.finance.yahoo.com/quote/IQV/
IQVIA Holdings Inc. (IQV) is currently trading at $262.69, up 1.64%, with a market capitalization of $43.291 billion. The company, a provider of clinical research and healthcare intelligence services, has shown a year-to-date return of 16.52%. Analysts have an average 1-year target price of $311.89 for IQV, with recent ratings maintaining a "Buy" recommendation.
Advertisement

IQVIA Holdings Inc. (IQV) Seasonal returns chart

https://uk.finance.yahoo.com/quote/IQV/seasonality/
This article from Yahoo Finance focuses on the historical seasonality of IQVIA Holdings Inc. (IQV). It presents a chart showing the average monthly price return for the company's stock between 2016 and 2026, indicating trends over 3, 5, 10, and 20 years. The article provides current stock performance data and links to various financial analysis tools for IQV.

Thermo Fisher Scientific (TMO) Gains Fresh Investor Focus In AI Led Genomics Screening

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-gains-fresh-investor-focus-in-a
Thermo Fisher Scientific is gaining investor attention for its role as a key supplier in global population genomic screening and viral genome sequencing, with its equipment supporting AI and precision medicine workflows. This reinforces a bullish view that AI-driven demand will lead to recurring revenue from instruments and consumables. However, the company also faces increased exposure to capital-intensive programs and existing concerns about high debt and high expectations.

IQVIA Holdings Inc. stock underperforms Friday when compared to competitors

https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-friday-when-compared-to-competitors-b32862e2-b4fa20af5c76?mod=mw_quote_news
Shares of IQVIA Holdings Inc. (IQV) fell 2.81% on Friday, closing at $267.33, amidst a broad market decline. The S&P 500 Index (SPX) dropped 1.82%, and the Dow Jones Industrial Average (DJIA) decreased by 1.09%, marking the stock's second consecutive day of losses.

Analysts’ Top Healthcare Picks: Perrigo Company (PRGO), IQVIA Holdings (IQV)

https://www.theglobeandmail.com/investing/markets/stocks/IQV/pressreleases/8532290/analysts-top-healthcare-picks-perrigo-company-prgo-iqvia-holdings-iqv/
Two analysts have issued bullish sentiments on healthcare stocks Perrigo Company (PRGO) and IQVIA Holdings (IQV). Susan Anderson from Canaccord Genuity maintained a Buy rating on Perrigo Company, while Stifel Nicolaus analyst Shlomo Rosenbaum maintained a Buy rating on IQVIA Holdings with a price target of $303.00. The analyst consensus for Perrigo Company is a Moderate Buy, and for IQVIA Holdings, it's a Strong Buy with a 15.0% upside.

Analysts’ Top Healthcare Picks: Perrigo Company (PRGO), IQVIA Holdings (IQV)

https://www.theglobeandmail.com/investing/markets/stocks/IQV-N/pressreleases/8532290/analysts-top-healthcare-picks-perrigo-company-prgo-iqvia-holdings-iqv/
Canaccord Genuity maintained a Buy rating on Perrigo Company (PRGO), with analyst Susan Anderson highlighting the company's strong performance. Stifel Nicolaus analyst Shlomo Rosenbaum also maintained a Buy rating on IQVIA Holdings (IQV), setting a price target of $303.00, while TipRanks – Anthropic upgraded the stock to Buy with a $302.00 price target. Both companies received positive analyst consensus ratings, indicating optimism in the Healthcare sector.
Advertisement

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Repligen (RGEN) and Cooper Co (COO)

https://www.theglobeandmail.com/investing/markets/stocks/IQV/pressreleases/8526701/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-repligen-rgen-and-cooper-co-coo/
Analysts have provided varied ratings for three healthcare companies. RBC Capital reiterated a Buy rating for IQVIA Holdings with a price target of $319.00, while also maintaining a Buy rating for Repligen with a $200.00 price target. Piper Sandler, however, maintained a Hold rating on Cooper Co with a price target of $59.00.

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Jazz Pharmaceuticals (JAZZ) and Repligen (RGEN)

https://www.theglobeandmail.com/investing/markets/stocks/IQV-N/pressreleases/8527817/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-jazz-pharmaceuticals-jazz-and-repligen-rgen/
Three analysts from UBS have issued bullish ratings for IQVIA Holdings (IQV), Jazz Pharmaceuticals (JAZZ), and Repligen (RGEN). Kevin Caliendo maintained a Buy rating on IQVIA Holdings with a $345.00 price target, Ashwani Verma set a Buy rating on Jazz Pharmaceuticals with a $337.00 price target, and Doug Schenkel maintained a Buy rating on Repligen with a $235.00 price target. All three companies received a "Strong Buy" analyst consensus, indicating significant upside potential based on current price targets.

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

https://www.tradingview.com/news/prnewswire:eb664e82181f5:0-labcorp-reports-strong-2026-third-quarter-results-raises-full-year-2026-guidance/
Labcorp announced strong third-quarter 2026 results, including a 6.9% increase in revenue to $3.81 billion and a 14.5% rise in adjusted EPS to $4.78. The company raised its full-year 2026 guidance for enterprise revenue growth and adjusted EPS, reflecting robust performance and strategic acquisitions. Labcorp also highlighted advancements in specialty testing and expanded partnerships, reinforcing its position in diagnostics and biopharma laboratory services.

Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and TG Therapeutics (TGTX)

https://www.theglobeandmail.com/investing/markets/stocks/IQV/pressreleases/8490306/analysts-offer-insights-on-healthcare-companies-elanco-animal-health-elan-iqvia-holdings-iqv-and-tg-therapeutics-tgtx/
This article provides an overview of recent analyst ratings for three healthcare companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV), and TG Therapeutics (TGTX). UBS maintained a Buy rating on Elanco, while BTIG maintained a Hold rating on IQVIA Holdings. J.P. Morgan also maintained a Buy rating on TG Therapeutics, with all three companies showing a general consensus of "Buy" or "Strong Buy" among analysts.

Rothschild & Co Redburn Adjusts Price Target on IQVIA Holdings to $299 From $287

https://www.moomoo.com/news/post/1002642321/rothschild-co-redburn-adjusts-price-target-on-iqvia-holdings-to
Rothschild & Co Redburn has increased its price target for IQVIA Holdings (IQV) from $287 to $299. The firm maintained a Buy rating on the stock, indicating continued confidence in the company's performance. This adjustment reflects a positive outlook on IQVIA Holdings' future valuation.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement